Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving Anti-CD19 CAR T-cell Therapy

Gray Jodon,Meryl D Colton,Diana Abbott,Anthony Cai,Bradley Haverkos,Rustain Morgan,Manali Kamdar

Clinical Lymphoma Myeloma and Leukemia（2023）

引用 3|浏览0

暂无评分

摘要

Clinical variables identify R/R lymphoma patients who are at risk for progression and poor overall survival after CAR T-cell therapy. IPI, CRP, ALC, and tocilizumab administration may be predictors of survival.

查看译文

关键词

Non-Hodgkin's lymphoma,adoptive cellular therapy,prediction,model,prognostic

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要